<DOC>
	<DOCNO>NCT00196404</DOCNO>
	<brief_summary>This placebo-controlled , double-blind study evaluate safety efficacy two dose DR-3001 woman overactive bladder symptom predominant pure urge incontinence , urinary urgency elevate urinary frequency</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy DR-3001 Versus Placebo Women With Overactive Bladder</brief_title>
	<detailed_description>This multi-center , randomize , placebo-controlled study compare two dos DR-3001 placebo 12-week treatment period . The overall duration patient participation approximately 19 week . Patients required keep daily diary record study medication use incontinence episode</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Diagnosis overactive bladder incontinence least 6 month Using birth control menopausal Willing discontinue current medication overactive bladder Pregnant give birth last 6 month Three urinary tract infection year Uncontrolled glaucoma , hypertension , diabetes myasthenia gravis History bladder cancer , ulcerative colitis severe constipation Any contraindication vaginal delivery system</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>urge incontinence</keyword>
	<keyword>urinary incontinence</keyword>
</DOC>